In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

ValiRx gets rights to CRT's prostate cancer compound

Executive Summary

Cancer Research UK's Cancer Research Technology Ltd. has licensed public biotech ValiRx PLC exclusive worldwide rights to develop and commercialize a peptide therapeutic aimed at hormone-resistant prostate cancer and other potential indications.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register